The Survival Outcomes, Prognostic Factors and Adverse Events following Systemic Chemotherapy Treatment in Bone Sarcomas: A Retrospective Observational Study from the Experience of the Cancer Referral Center in Northern Thailand
This study aimed to assess survival outcomes, prognostic factors, and adverse events following chemotherapy treatment for osteosarcoma and Ewing’s sarcoma. This retrospective observational study was conducted to collect the data of the patients with osteosarcoma or Ewing’s sarcoma who received chemo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/7/1979 |
| _version_ | 1797608246272327680 |
|---|---|
| author | Wachiranun Sirikul Nida Buawangpong Dumnoensun Pruksakorn Chaiyut Charoentum Pimpisa Teeyakasem Nut Koonrungsesomboon |
| author_facet | Wachiranun Sirikul Nida Buawangpong Dumnoensun Pruksakorn Chaiyut Charoentum Pimpisa Teeyakasem Nut Koonrungsesomboon |
| author_sort | Wachiranun Sirikul |
| collection | DOAJ |
| description | This study aimed to assess survival outcomes, prognostic factors, and adverse events following chemotherapy treatment for osteosarcoma and Ewing’s sarcoma. This retrospective observational study was conducted to collect the data of the patients with osteosarcoma or Ewing’s sarcoma who received chemotherapy treatment between 2008 and 2019. The flexible parametric survival model was performed to explore the adjusted survival probability and the prognostic factors. A total of 102 patients (79 with osteosarcoma and 23 with Ewing’s sarcoma) were included. The estimated 5-year disease-free survival (DFS) and 5-year overall survival (OS) probabilities in patients with resectable disease were 60.9% and 63.3% for osteosarcoma, and 54.4% and 88.3% for Ewing’s sarcoma, respectively, whereas the 5-year DFS and 5-year OS for those with unresectable/metastatic disease remained below 25%. Two prognostic factors for osteosarcoma included a response to neoadjuvant chemotherapy and female gender. Ewing’s sarcoma patients aged 25 years and older were significantly associated with poorer survival outcomes. Of 181 chemotherapy treatment cycles, common self-reported adverse symptoms included tumor pain (<i>n</i> = 32, 17.7%), fever (<i>n</i> = 21, 11.6%), and fatigue (<i>n</i> = 16, 8.8%), while common grade III adverse events included febrile neutropenia (<i>n</i> = 13, 7.3%) and neutropenia (<i>n</i> = 9, 5.1%). There was no chemotherapy-related mortality (grade V) or anaphylaxis events. |
| first_indexed | 2024-03-11T05:41:52Z |
| format | Article |
| id | doaj.art-667f2f4160c843b09189375a691a42d0 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T05:41:52Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-667f2f4160c843b09189375a691a42d02023-11-17T16:24:23ZengMDPI AGCancers2072-66942023-03-01157197910.3390/cancers15071979The Survival Outcomes, Prognostic Factors and Adverse Events following Systemic Chemotherapy Treatment in Bone Sarcomas: A Retrospective Observational Study from the Experience of the Cancer Referral Center in Northern ThailandWachiranun Sirikul0Nida Buawangpong1Dumnoensun Pruksakorn2Chaiyut Charoentum3Pimpisa Teeyakasem4Nut Koonrungsesomboon5Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDepartment of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDepartment of Orthopedic, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDivision of Oncology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDepartment of Orthopedic, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandCenter of Multidisciplinary Technology for Advanced Medicine (CMUTEAM), Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandThis study aimed to assess survival outcomes, prognostic factors, and adverse events following chemotherapy treatment for osteosarcoma and Ewing’s sarcoma. This retrospective observational study was conducted to collect the data of the patients with osteosarcoma or Ewing’s sarcoma who received chemotherapy treatment between 2008 and 2019. The flexible parametric survival model was performed to explore the adjusted survival probability and the prognostic factors. A total of 102 patients (79 with osteosarcoma and 23 with Ewing’s sarcoma) were included. The estimated 5-year disease-free survival (DFS) and 5-year overall survival (OS) probabilities in patients with resectable disease were 60.9% and 63.3% for osteosarcoma, and 54.4% and 88.3% for Ewing’s sarcoma, respectively, whereas the 5-year DFS and 5-year OS for those with unresectable/metastatic disease remained below 25%. Two prognostic factors for osteosarcoma included a response to neoadjuvant chemotherapy and female gender. Ewing’s sarcoma patients aged 25 years and older were significantly associated with poorer survival outcomes. Of 181 chemotherapy treatment cycles, common self-reported adverse symptoms included tumor pain (<i>n</i> = 32, 17.7%), fever (<i>n</i> = 21, 11.6%), and fatigue (<i>n</i> = 16, 8.8%), while common grade III adverse events included febrile neutropenia (<i>n</i> = 13, 7.3%) and neutropenia (<i>n</i> = 9, 5.1%). There was no chemotherapy-related mortality (grade V) or anaphylaxis events.https://www.mdpi.com/2072-6694/15/7/1979sarcomaosteosarcomaEwing’s sarcomachemotherapysurvival rateprognosis |
| spellingShingle | Wachiranun Sirikul Nida Buawangpong Dumnoensun Pruksakorn Chaiyut Charoentum Pimpisa Teeyakasem Nut Koonrungsesomboon The Survival Outcomes, Prognostic Factors and Adverse Events following Systemic Chemotherapy Treatment in Bone Sarcomas: A Retrospective Observational Study from the Experience of the Cancer Referral Center in Northern Thailand Cancers sarcoma osteosarcoma Ewing’s sarcoma chemotherapy survival rate prognosis |
| title | The Survival Outcomes, Prognostic Factors and Adverse Events following Systemic Chemotherapy Treatment in Bone Sarcomas: A Retrospective Observational Study from the Experience of the Cancer Referral Center in Northern Thailand |
| title_full | The Survival Outcomes, Prognostic Factors and Adverse Events following Systemic Chemotherapy Treatment in Bone Sarcomas: A Retrospective Observational Study from the Experience of the Cancer Referral Center in Northern Thailand |
| title_fullStr | The Survival Outcomes, Prognostic Factors and Adverse Events following Systemic Chemotherapy Treatment in Bone Sarcomas: A Retrospective Observational Study from the Experience of the Cancer Referral Center in Northern Thailand |
| title_full_unstemmed | The Survival Outcomes, Prognostic Factors and Adverse Events following Systemic Chemotherapy Treatment in Bone Sarcomas: A Retrospective Observational Study from the Experience of the Cancer Referral Center in Northern Thailand |
| title_short | The Survival Outcomes, Prognostic Factors and Adverse Events following Systemic Chemotherapy Treatment in Bone Sarcomas: A Retrospective Observational Study from the Experience of the Cancer Referral Center in Northern Thailand |
| title_sort | survival outcomes prognostic factors and adverse events following systemic chemotherapy treatment in bone sarcomas a retrospective observational study from the experience of the cancer referral center in northern thailand |
| topic | sarcoma osteosarcoma Ewing’s sarcoma chemotherapy survival rate prognosis |
| url | https://www.mdpi.com/2072-6694/15/7/1979 |
| work_keys_str_mv | AT wachiranunsirikul thesurvivaloutcomesprognosticfactorsandadverseeventsfollowingsystemicchemotherapytreatmentinbonesarcomasaretrospectiveobservationalstudyfromtheexperienceofthecancerreferralcenterinnorthernthailand AT nidabuawangpong thesurvivaloutcomesprognosticfactorsandadverseeventsfollowingsystemicchemotherapytreatmentinbonesarcomasaretrospectiveobservationalstudyfromtheexperienceofthecancerreferralcenterinnorthernthailand AT dumnoensunpruksakorn thesurvivaloutcomesprognosticfactorsandadverseeventsfollowingsystemicchemotherapytreatmentinbonesarcomasaretrospectiveobservationalstudyfromtheexperienceofthecancerreferralcenterinnorthernthailand AT chaiyutcharoentum thesurvivaloutcomesprognosticfactorsandadverseeventsfollowingsystemicchemotherapytreatmentinbonesarcomasaretrospectiveobservationalstudyfromtheexperienceofthecancerreferralcenterinnorthernthailand AT pimpisateeyakasem thesurvivaloutcomesprognosticfactorsandadverseeventsfollowingsystemicchemotherapytreatmentinbonesarcomasaretrospectiveobservationalstudyfromtheexperienceofthecancerreferralcenterinnorthernthailand AT nutkoonrungsesomboon thesurvivaloutcomesprognosticfactorsandadverseeventsfollowingsystemicchemotherapytreatmentinbonesarcomasaretrospectiveobservationalstudyfromtheexperienceofthecancerreferralcenterinnorthernthailand AT wachiranunsirikul survivaloutcomesprognosticfactorsandadverseeventsfollowingsystemicchemotherapytreatmentinbonesarcomasaretrospectiveobservationalstudyfromtheexperienceofthecancerreferralcenterinnorthernthailand AT nidabuawangpong survivaloutcomesprognosticfactorsandadverseeventsfollowingsystemicchemotherapytreatmentinbonesarcomasaretrospectiveobservationalstudyfromtheexperienceofthecancerreferralcenterinnorthernthailand AT dumnoensunpruksakorn survivaloutcomesprognosticfactorsandadverseeventsfollowingsystemicchemotherapytreatmentinbonesarcomasaretrospectiveobservationalstudyfromtheexperienceofthecancerreferralcenterinnorthernthailand AT chaiyutcharoentum survivaloutcomesprognosticfactorsandadverseeventsfollowingsystemicchemotherapytreatmentinbonesarcomasaretrospectiveobservationalstudyfromtheexperienceofthecancerreferralcenterinnorthernthailand AT pimpisateeyakasem survivaloutcomesprognosticfactorsandadverseeventsfollowingsystemicchemotherapytreatmentinbonesarcomasaretrospectiveobservationalstudyfromtheexperienceofthecancerreferralcenterinnorthernthailand AT nutkoonrungsesomboon survivaloutcomesprognosticfactorsandadverseeventsfollowingsystemicchemotherapytreatmentinbonesarcomasaretrospectiveobservationalstudyfromtheexperienceofthecancerreferralcenterinnorthernthailand |